Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

NCT03285321 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

105

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Greg Durm, MD

Collaborators

[object Object]
[object Object]